# Aurinia Pharmaceuticals Inc (AUPH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.08, market value $2.1 billion.

## Valuation
- **P/E (trailing): 7.1×** (5-yr avg 116.1×, 3-yr avg 116.1×). Aurinia Pharmaceuticals Inc trades at 7.1× trailing earnings, well below its own five-year average of 116.1×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.1×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.9×**. Each dollar of revenue is priced at 6.9×.
- **Price / book: 3.5×**. The shares trade at 3.5× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 14.2%**. The inverse of the P/E: 14.2% of the price is earned each year.

## Profitability
- **Operating margin: 48.4%**. 48.4% of revenue is left after running the business, an exceptional level.
- **Net margin: 101.5%**. 101.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 49.4%**. 49.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 41.8%**. Each dollar of assets produces 41.8% of profit.

## Growth
- **Revenue growth (1 yr): 20.4%** (3-yr 28.3%/yr, 5-yr 41.4%/yr). Revenue grew 20.4% over the last year, against 41.4% a year compounded over five years: growth is slowing.

## Financial health
- **Current ratio: 5.25** (quick 5.25). Current assets cover the next year's liabilities 5.25 times.
- **Altman Z-score: 10.10**. A Z-score of 10.10 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Aurinia Pharmaceuticals Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Aurinia Pharmaceuticals Inc; the consensus is strong_buy, with an average price target of $17.86 (+11% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 28.3%** (YTD 0.8%, 3-mo 1.5%). The shares are up 28.3% over twelve months including dividends.
- **From 52-week high: -16.5%** (55.5% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.69** (volatility 41%). Beta of 0.69 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AUPH · Page: https://foliofundamentals.com/stocks/auph

Not investment advice.